ISRCTN15113276 https://doi.org/10.1186/ISRCTN15113276

A Randomised Trial of Adriamycin and Taxotere vs. Adriamycin and Cyclophosphamide in Breast Cancer

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 30/05/2012	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
BR 9809

Study information

Scientific Title

Study objectives
Added 12/02/10:
To compare the clinical and pathologic response rates of doxorubicin and cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in women with primary or locally advanced breast cancer.

Please note that as of 12/02/10 this record has been updated. All changes can be found in the relevant field with the above update date.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Breast cancer

Interventions
1. Adriamycin 50 mg/m^2 intravenous (iv) 3 weekly + taxotere 75 mg/m^2 iv 3 weekly (NB Taxotere must be administered prior to Adriamycin)
2. Adriamycin (60 mg/m^2 iv) 3 weekly + cyclophosphamide (600 mg/m^2 iv) weekly. Maximum of 6 cycles of combination chemotherapy.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Doxorubicin (Adriamycin®), docetaxel (Taxotere®), cyclophosphamide

Primary outcome(s)
Added 12/02/10:
Overall (complete and partial) clinical response rates

Key secondary outcome(s))
Added 12/02/10:
Number of relapses

Completion date

01/07/2002

Eligibility

Key inclusion criteria
1. Histologically proven breast cancer (BrCa)
2. Potentially operable disease >3cm diameter, locally advanced disease (including T4 lesions) or inflammatory BrCa
3. Patients older then 18 years

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
Female

Key exclusion criteria
Does not match inclusion criteria

Date of first enrolment
01/07/1999

Date of final enrolment
01/07/2002

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Scottish Cancer Therapy Network (UK)

Funder(s)

Funder type
Research organisation

Funder Name
Scottish Cancer Therapy Network (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2005		Yes	No